Title :

Transcarotid approach for transcatheter�aortic valve replacement with the sapien 3 prosthesis: a multicenter french registry

Author(s) :

Overtchouk, Pavel [Auteur]
Folliguet, Thierry [Auteur]
Pinaud, Frederic [Auteur]
Fouquet, Oliver [Auteur]
Pernot, Mathieu [Auteur]
Bonnet, Guillaume [Auteur]
Hubert, Maxime [Auteur]
Lapeze, Joel [Auteur]
Claudel, Jean-Philippe [Auteur]
Ghostine, Said [Auteur]
Azmoun, Alexandre [Auteur]
Caussin, Christophe [Auteur]
Zannis, Konstantinos [Auteur]
Harmouche, Majid [Auteur]
Verhoye, Jean-Philippe [Auteur]
Lafont, Antoine [Auteur]
Chamandi, Chekrallah [Auteur]
Ruggieri, Vito Giovanni [Auteur]
Di Cesare, Alessandro [Auteur]
Leclercq, Florence [Auteur]
Gandet, Thomas [Auteur]
Modine, Thomas [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 [TCDV]

Journal title :

JACC. Cardiovascular interventions

Abbreviated title :

JACC Cardiovasc Interv

Publication date :

2019-02-07

ISSN :

1876-7605

English keyword(s) :

Sapien 3
transcarotid
TAVR

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

OBJECTIVE: This study sought to describe the procedural and clinical outcomes of patients undergoing transcarotid (TC) transcatheter aortic valve replacement (TAVR) with the Edwards Sapien 3 device. BACKGROUND: The TC ...
Show more >OBJECTIVE: This study sought to describe the procedural and clinical outcomes of patients undergoing transcarotid (TC) transcatheter aortic valve replacement (TAVR) with the Edwards Sapien 3 device. BACKGROUND: The TC approach for TAVR holds the potential to become the optimal alternative to the transfemoral gold standard. Limited data exist regarding safety and efficacy of TC-TAVR using the Edwards Sapien 3 device. METHODS: The French Transcarotid TAVR prospective multicenter registry included patients between 2014 and 2018. Consecutive patients treated in 1 of the 13 participating centers ineligible for transfemoral TAVR were screened for TC-TAVR. Clinical and echocardiographic data were prospectively collected. Perioperative and 30-day outcomes were reported according to the updated Valve Academic Research Consortium (VARC-2). RESULTS: A total of 314 patients were included with a median (interquartile range) age of 83 (78 to 88) years, 63% were males, Society of Thoracic Surgeons mortality risk score 5.8% (4% to 8.3%). Most patients presented with peripheral artery disease (64%). TC-TAVR was performed under general anesthesia in 91% of cases, mostly using the left carotid artery (73.6%) with a procedural success of 97%. Three annulus ruptures were reported, all resulting in patient death. At 30 days, rates of major bleeding, new permanent pacemaker, and stroke or transient ischemic attack were 4.1%, 16%, and 1.6%, respectively. The 30-day mortality was 3.2%. CONCLUSIONS: TC-TAVR using the Edwards Sapien 3 device was safe and effective in this prospective multicenter registry. The TC approach might be considered, in selected patients, as the first-line alternative approach for TAVR whenever the transfemoral access is prohibited. Sapien 3 device was safe and effective in our multicenter cohort.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2019-11-27T14:30:11Z